Francesco de Rubertis, a co-founder of Medicixi Ventures, has unveiled the next generation of the venture-backed asset-centric biopharma model with the creation of Centessa Pharmaceuticals Ltd. The new company was created by acquiring, in all-share transactions, total control of 10 companies from the Medicxi portfolio. Read more at BioWorld.com
CEO Neil Clark and CSO Dr Bill Love from Europe’s leading anti-infectives biotech company Destiny Pharma, on how the makers and influencers of health policy could fuel a renaissance in drug development…
Novo Seeds had a very successful year with five investments. Also, substantial progress has been made across the 25 biotech companies in the portfolio, with 12 drug candidates now in the clinic.
2021: Priorities for European Pharma & What does the investment landscape look like post Covid-19?
From surviving to thriving as 2021 takes the reins from 2020. In a year turned on its head by the pandemic, witnessing this month the unprecedented roll out of a novel coronavirus vaccine, with several more vaccines on the horizon, December has become a time of hope…
